Can CVS Health Buy BioPharmX Corporation?


Can CVS Health Buy BioPharmX Corporation? –

  • Corporate health-care deal value surged 37 percent last year, according to a new report from consulting firm Bain & Company.
  • The number of health-care mergers and acquisitions rose 16 percent.
  • CVS Health’s planned acquisition of health insurer Aetna was the largest corporate deal of 2017 at $69 billion.

The health-care shopping spree isn’t likely to stop anytime soon.

Corporate deal value surged to $332 billion last year, up 27 percent from $261 billion in 2016, though still below the peak of $432 billion in 2015, according to a new report from consulting firm Bain & Company.

What does make BioPharmX unique?

  1. Financial Health: Does it have a healthy balance sheet?
  2. Management:Have insiders been ramping up their shares to take advantage of the market’s sentiment for BPMX’s future outlook?
  3. Other High-Growth Alternatives: BPMX is a high-growth stock you could be holding?

Walgreens  was also reportedly considering acquiring the part of drug distributor AmerisourceBergen that it doesn’t already own earlier this year, though talks have cooled. Walmart and health insurer Humana are having early-stage talks about strengthening their existing partnership, people familiar with the matter told CNBC.

BioPharmX Corporation (BPMX) products are sold in CVS Health Pharmacy (NYSE:CVS),

Walgreens,, GNC (NYSE:GNC), The Vitamin Shoppe, Harris Teeter and many more.

BioPharmX added 3,025 GNC store locations supplying Violet® iodine, raising its
U.S. retail footprint to more than 7,500 stores. Availability of Violet iodine at GNC is expected to begin in
mid-December. GNC is a leading global specialty retailer of health and wellness products and is devoted to helping its
customers improve the quality of their lives. We believe the addition of GNC stores will accelerate VI2OLET revenue growth in the coming quarters.

Institutional investors currently hold major shares in BioPharmX Corporation(BPMX) stock. Majority of the recent share have been purchased by Vanguard Investment firm on 5-13-2018

Owner NameDateShared HeldChange (Shares)Change (%)Value (in 1,000s)
VIVO CAPITAL, LLC05/13/201816,128,5152,328,57116.873,306
FRANKLIN RESOURCES INC05/13/20189,749,61500.001,999
VANGUARD GROUP INC05/13/20185,498,9183,541,971181.001,127
GEODE CAPITAL MANAGEMENT, LLC03/31/2018671,686347,719107.33138
VIRTU FINANCIAL LLC03/31/2018426,837426,837New88
BARCLAYS PLC03/31/2018362,900362,900New74
CITADEL ADVISORS LLC03/31/2018146,859146,859New30
MCF ADVISORS LLC03/31/2018105,629105,629New22
JANE STREET GROUP, LLC03/31/201896,94196,941New20
TWO SIGMA SECURITIES, LLC03/31/201893,39047,105101.7719
NORTHERN TRUST CORP03/31/201892,51800.0019
UBS GROUP AG03/31/201870,36736,614108.4814
CREDIT SUISSE AG/03/31/201850,00050,000New10
Increased Positions177,708,826
Held Positions715,447,095
Total Institutional Shares2733,878,519

 Institutional Ownership

Institutions own approximately 19.42% of BioPharmX’ shares. Among active positions in the latest quarter, 7 holders increased their positions by a total of 10.8 million shares. This means there is a net increase in ownership of 9.61 million shares, which may suggest that institutions feel bullish about the stock.

 Cash as of March 9, 2018

  • Pro-forma cash of $14.2 million
    • $8.6 million as of January 31, 2018
    • $6.7 million in proceeds from warrant exercises after the end of the quarter

 Reverse Split

The company let an already approved reverse split expire.

“Regarding the expired reverse stock split, the company and its shareholders did not feel such an action would be in the best interest of the shareholders once the company was able to bring the company back into compliance with the NYSE American’s continued listing standards. The company is optimistic that it will be in compliance for continued listing standards regarding its share price by the June deadline.”


Institutional ownership trends suggest that the stock is cheap and the insider trading data indicates that insiders are bullish. Technical indicators also suggest that BioPharmX Corporation (BPMX) , is undervalued. 

A potential Buy is very possible for BioPharmX Corporation by a major Drug chain like CVS or Walgreens Pharmacy.

CWEB Analysts have Reiterate a Buy Rating for BioPharmX Corporation (BPMX)  and a Price Target of $7 within 12 months.



Comments is not registered as an investment adviser with the U.S. Securities and Exchange Commission. Rather, relies upon the “publisher’s exclusion” from the definition of investment adviser as provided under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws.

Full Disclaimer

%d bloggers like this: